Atara Biotherapeutics, Inc. (ATRA) Downgraded by ValuEngine

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, August 1st.

ATRA has been the topic of several other reports. Canaccord Genuity reiterated a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a research report on Friday, April 21st. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Finally, Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 9th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Atara Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $25.75.

Atara Biotherapeutics (NASDAQ:ATRA) traded up 1.72% on Tuesday, reaching $14.75. 146,964 shares of the company were exchanged. The firm’s market capitalization is $450.75 million. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $23.40. The firm has a 50-day moving average of $15.02 and a 200 day moving average of $15.88.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by $0.05. On average, equities analysts predict that Atara Biotherapeutics will post ($3.88) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.com-unik.info/2017/08/11/atara-biotherapeutics-inc-atra-rating-lowered-to-strong-sell-at-valuengine-updated.html.

In related news, EVP Gad Soffer sold 12,674 shares of the firm’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $15.16, for a total transaction of $192,137.84. Following the completion of the transaction, the executive vice president now directly owns 259,527 shares of the company’s stock, valued at $3,934,429.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 2,800 shares of the firm’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $16.94, for a total transaction of $47,432.00. Following the transaction, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at $12,397,691.46. The disclosure for this sale can be found here. Insiders have sold a total of 54,308 shares of company stock worth $797,382 over the last 90 days. Insiders own 16.10% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP boosted its position in Atara Biotherapeutics by 2.9% in the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 610 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in Atara Biotherapeutics by 16.9% in the second quarter. Parametric Portfolio Associates LLC now owns 29,682 shares of the biotechnology company’s stock valued at $416,000 after buying an additional 4,293 shares during the last quarter. Vanguard Group Inc. boosted its position in Atara Biotherapeutics by 1.7% in the second quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock valued at $11,842,000 after buying an additional 13,952 shares during the last quarter. Northern Trust Corp boosted its position in Atara Biotherapeutics by 12.0% in the second quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock valued at $4,183,000 after buying an additional 32,065 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Atara Biotherapeutics by 7.4% in the second quarter. TIAA CREF Investment Management LLC now owns 67,892 shares of the biotechnology company’s stock valued at $950,000 after buying an additional 4,661 shares during the last quarter. 81.50% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit